Smoking is associated with worse outcomes of COVID-19 particularly among younger adults: a systematic review and meta-analysis
Abstract Background Smoking impairs lung immune function and damages upper airways, increasing risks of contracting and severity of infectious diseases. This paper quantifies the association between smoking and COVID-19 disease progression. Methods We searched PubMed and Embase for studies published...
-д хадгалсан:
Үндсэн зохиолчид: | , |
---|---|
Формат: | Ном |
Хэвлэсэн: |
BMC,
2021-08-01T00:00:00Z.
|
Нөхцлүүд: | |
Онлайн хандалт: | Connect to this object online. |
Шошгууд: |
Шошго нэмэх
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_d21c5aafa2c14fed97c5ed20ae8d1c20 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Roengrudee Patanavanich |e author |
700 | 1 | 0 | |a Stanton A. Glantz |e author |
245 | 0 | 0 | |a Smoking is associated with worse outcomes of COVID-19 particularly among younger adults: a systematic review and meta-analysis |
260 | |b BMC, |c 2021-08-01T00:00:00Z. | ||
500 | |a 10.1186/s12889-021-11579-x | ||
500 | |a 1471-2458 | ||
520 | |a Abstract Background Smoking impairs lung immune function and damages upper airways, increasing risks of contracting and severity of infectious diseases. This paper quantifies the association between smoking and COVID-19 disease progression. Methods We searched PubMed and Embase for studies published from January 1-May 25, 2020. We included studies reporting smoking behavior of COVID-19 patients and progression of disease, including death. We used random effects meta-analysis, meta-regression and locally weighted regression and smoothing to examine relationships in the data. Results We identified 46 peer-reviewed papers with a total of 22,939 COVID-19 patients, 5421 (23.6%) experienced disease progression and 2914 (12.7%) with a history of smoking (current and former smokers). Among those with a history of smoking, 33.5% experienced disease progression, compared with 21.9% of non-smokers. The meta-analysis confirmed an association between ever smoking and COVID-19 progression (OR 1.59, 95% CI 1.33-1.89, p = 0.001). Ever smoking was associated with increased risk of death from COVID-19 (OR 1.19, 95% CI 1.02-1.39, p = 0.003). We found no significant difference (p = 0.864) between the effects of ever smoking on COVID-19 disease progression between adjusted and unadjusted analyses, suggesting that smoking is an independent risk factor for COVID-19 disease progression. We also found the risk of having COVID-19 progression higher among younger adults (p = 0.001), with the effect most pronounced among younger adults under about 45 years old. Conclusions Smoking is an independent risk for having progression of COVID-19, including mortality. The effects seem to be higher among young people. Smoking prevention and cessation should remain a priority for the public, physicians, and public health professionals during the COVID-19 pandemic. | ||
546 | |a EN | ||
690 | |a COVID-19 | ||
690 | |a Coronavirus | ||
690 | |a Meta-analysis | ||
690 | |a Disease progression | ||
690 | |a Odds ratio | ||
690 | |a Death | ||
690 | |a Public aspects of medicine | ||
690 | |a RA1-1270 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n BMC Public Health, Vol 21, Iss 1, Pp 1-9 (2021) | |
787 | 0 | |n https://doi.org/10.1186/s12889-021-11579-x | |
787 | 0 | |n https://doaj.org/toc/1471-2458 | |
856 | 4 | 1 | |u https://doaj.org/article/d21c5aafa2c14fed97c5ed20ae8d1c20 |z Connect to this object online. |